📌 New treatment algorithm in the treatment of metastatic breast cancer in 2024 👉🏻Triple negative breast cancer❗️ now 🔛 By G Curigliano MD PhD 👏🏻 #ESMO24 OncoAlert #OncoAlertAF

DESTINY-Breast12, the largest prospective study of T-DXd in HER2+ mBC with brain metastases presented by Nancy Lin, MD shows 12-mo PFS of 61.6% & CNS PFS of 58.9% in BM cohort. CNS ORR: 79.2% (stable) & 62.3% (active). ILD/pneumonitis: 16.0% in BM, 12.9% in non-BM cohort OncoAlert

At #ESMO24 Nancy Lin, MD presents data on T-DXd in Destiny-Breast12 T-DXd showed substantial overall and intracranial clinical activity in pts with HER2+ mBC 🧠 Median PFS 17.3 mos and CNS ORR 72% in pts with baseline brain mets OncoAlert

DESTINY breast 12 Nancy Lin, MD #ESMO24 ▪️ 12 month PFS overall, similiar w stable and active brain mets 62.9% & 59.6% ▪️ median PFS = 17.3 mon ▪️CNS ORR = 71.7% ▪️12-month OS was maintained in patients with BMs (90.3%) and without BMs (90.6%)

Impressive IC activity of T-DXd for HER2+ MBC in #DB12 presented by Nancy Lin, MD. mPFS=17 months, CNS-ORR =71.7%. Confirms the preferred 2L option for pts with HER2+ MBC. 9 G5 cases of ILD remind us of the importance of careful monitoring. Concomitant publication in Nature Medicine!

At #ESMO24 Barbara Pistilli presents ICARUS-BREAST01, phase II study of patritumab deruxtecan (HER3-DXd) in HR+/HER2- advanced breast cancer Clinically meaningful activity in pretreated patients (median 2 prior lines) with ORR 53.5%, and mPFS 9.4 mos OncoAlert

Great recap of 2L+ data for HER2+ mBC with brain mets by Cristina Saura. mPFS >14 months with T-DXd across studies (vs 7.8 months with the tucatinib triplet). Supports an earlier use of T-DXd in this setting, though ILD remains a concern. #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

📌 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial Meghna Trivedi, MD #ESMO24 OncoAlert #OncoAlertAF • Highest pCR rate observed in Immune+ (79%) followed by TNBC (62%) subtypes • > 50%

【Penicillin Allergy】NEJM 2019 👉A very useful review for understanding the true mechanisms of penicillin allergy 👉A must-read at least once for everyone! pubmed.ncbi.nlm.nih.gov/31826341/ #IDMedEd #IDFellow #Penicillin #Allergy

👑Presidential #ESMO24 -Practice changing trials ESMO - Eur. Oncology ➡️LEAP-012 Adding lenvatinib + pembro to TACE in intermediate-stage HCC ✅mPFS: 14.6 vs 10 mo; HR: 0.66, 95% CI: 0.51-0.84; P = 0.0002 ➡️OS immature ❗️Grade 3-5 TRAEs: 71.3% vs 31.5% OncoAlert #cancer #oncology #MedX

TACE +/- lenva + pembro for intermediate-stage HCC #ESMO24 🔎Phs III LEAP-012 👉ORR 46 vs 33% (RECIST) 👉ORR 71 vs 49% (mRECIST) 👉mPFS 10 vs 14.6 mo 👉mOS not mature 👉AE ≥3 31% vs 71% 🧐strong ORR and PFS data, already practice-changing? ESMO - Eur. Oncology #ESMOAmbassadors

Dr. Viale discusses HER2 testing in #bcsm 📌HER-2 null only 12% 📍94% of those scored HER-2 low locally were confirmed centrally in DB-06 pop 🔆of those IHC 0 locally, centrally 40% ultra low and 24% low 💣 low is being missed in our communities #ESMO24 #ESMOAmbassadors

Think you hear a lot about #ADCs now? Just wait....here we go 🏎️!!! 107 topo1 ADCs in development currently to at least 39 diff 🎯 AACR President Lillian L. Siu #ESMO24 #ESMOAmbassadors

Previously presented at #ASCO24 by G Curigliano MD PhD, the impressive results of DB06, testing T-DXd vs chemo for endocrine-refractory HR+ MBC, are now published in NEJM. Take home points ( 🧵 ): nejm.org/doi/full/10.10…

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! OncoAlert

Marleen Kok with very thoughtful discussion on the design of the KN522, : do all patients need adjuvant pembrolizumab; the irAEA especially in young women who would like to get pregnant. #ESMO2024 OncoAlert ESMO - Eur. Oncology Kevin Punie Matteo Lambertini, MD PhD Paolo Tarantino

Why didn’t Dato-DXd improve OS in HR+/HER2- mBC, a setting were a different Trop2 ADC (SG) has previously shown OS advantage? 3 potential, non-exclusive explanations 👇

Immune system one pager

How do we build a new generation of safer and more active ADCs for treating cancer? 👉By understanding how they actually work (and stop working) In this Cancer Discovery review, we retrace 40 years of ADC development, highlighting key lessons learned. 🧵 below aacrjournals.org/cancerdiscover…

#BehindThePaper 2/n None of the approved ADCs (to date) is fully stable in circulation There are 2 types of linker instabilities: 1) linker-drug instabilities, which release free drug 2) antibody-linker instabilities, which release the whole drug-linker doi.org/10.1158/2159-8…